LCTX

0.77195.87%
BM

Brian M. Culley

CEO, President & Director

Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim Chief Financial Officer at Lineage Cell Therapeutics, Inc. since January 20, 2021 until June 21, 2021. He serves as Chief Executive Officer at Artemis Therapeutics Inc. He serves as a President, Chief Executive Officer and Director of Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.) since September 17, 2018. He joined the Lineage Cell Therapeutics, Inc. on September 17, 2018. Mr. Culley served as Chief Executive Officer of Artemis Therapeutics Inc. from August 9, 2017 to August 10, 2018. He served as the Chief Executive Officer of Mast Therapeutics, Inc. since February 2010 until April 2017. He served as Chief Executive Officer of Savara Inc. He served as the Chief Business Officer and Senior Vice President at Adventrx Pharmaceuticals Inc. /Mast Therapeutics, Inc. from January 2007 to February 2010 and served as its Principal Executive Officer since February 2009, it is Senior Vice President of Business Development from February 2006 to January 2007 and its Vice President of Business Development from December 2004 to February 2006. Mr. Culley joined Adventrx Pharmaceuticals in December 2004. He served as the Interim Principal Executive Officer at Adventrx Pharmaceuticals Inc. since February 3, 2009. He served as a Vice President of Business Development of Adventrx Pharmaceuticals Inc. from December 2004 to February 2006. From 2002 to 2004, Mr. Culley managed all strategic collaborations and licensing agreements for iTherx, Inc. (formerly, Immusol, Inc.) in San Diego. He served as Director of Business Development & Marketing for Immusol, Inc., a privately-held drug development company in San Diego from 2002 to 2004. From 1999 to 2000, he served as a Licensing & Marketing Associate at the University of California, San Diego Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999, he served as a Research Associate for Neurocrine Biosciences Inc., where he performed drug discovery research. Mr. Culley has business and scientific experience in the life science industry. Mr. Culley served as a Director of Mast Therapeutics, Inc. since December 8, 2011 until April 2017. He received a BS in biology from Boston College, an M.S. in biochemistry and molecular biology from the University of California, Santa Barbara and an MBA from The Johnson School of Business at Cornell University with an emphasis on private equity and entrepreneurship.

Positions